158 related articles for article (PubMed ID: 18245642)
1. Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9.
Gröner A
Haematologica; 2008 Feb; 93(2):e24-6; author reply e27. PubMed ID: 18245642
[No Abstract] [Full Text] [Related]
2. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
Pereira A
Haematologica; 2007 Jun; 92(6):846-9. PubMed ID: 17550860
[TBL] [Abstract][Full Text] [Related]
3. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of fresh-frozen plasma and cryoprecipitate in neonatal intensive care unit.
Motta M; Del Vecchio A; Radicioni M
J Matern Fetal Neonatal Med; 2011 Oct; 24 Suppl 1():129-31. PubMed ID: 21942611
[TBL] [Abstract][Full Text] [Related]
5. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.
Erhabor O; Adias TC
Transfus Clin Biol; 2011 Dec; 18(5-6):516-26. PubMed ID: 22037104
[TBL] [Abstract][Full Text] [Related]
6. Cryoprecipitate use in 25 Canadian hospitals: commonly used outside of the published guidelines.
Alport EC; Callum JL; Nahirniak S; Eurich B; Hume HA
Transfusion; 2008 Oct; 48(10):2122-7. PubMed ID: 18764824
[TBL] [Abstract][Full Text] [Related]
7. The safe blood components for a hemophilia patient: a case report.
Chuansumrit A; Pandhawong S; Tardtong P; Isarangkura P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():198-200. PubMed ID: 7886573
[TBL] [Abstract][Full Text] [Related]
8. Plasma and plasma derivatives in therapeutic plasmapheresis.
McLeod BC
Transfusion; 2012 May; 52 Suppl 1():38S-44S. PubMed ID: 22578370
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia.
Idris SF; Hadjinicolaou AV; Sweeney M; Winthrop C; Balendran G; Besser M
Br J Haematol; 2014 Aug; 166(3):458-61. PubMed ID: 24725203
[No Abstract] [Full Text] [Related]
10. Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate.
Elliott BM; Aledort LM
Expert Rev Hematol; 2013 Jun; 6(3):277-86. PubMed ID: 23782082
[TBL] [Abstract][Full Text] [Related]
11. Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems.
Burnouf T; Radosevich M; El-Ekiaby M; Goubran H
Transfusion; 2011 Feb; 51(2):446-7; author reply 447-8. PubMed ID: 21309785
[No Abstract] [Full Text] [Related]
12. For: Fibrinogen concentrate for management of bleeding.
Rahe-Meyer N; Sørensen B
J Thromb Haemost; 2011 Jan; 9(1):1-5. PubMed ID: 20946151
[No Abstract] [Full Text] [Related]
13. Against: Fibrinogen concentrate for management of bleeding: against indiscriminate use.
Ozier Y; Hunt BJ
J Thromb Haemost; 2011 Jan; 9(1):6-8. PubMed ID: 21210948
[No Abstract] [Full Text] [Related]
14. [Safety of plasma-derived factor concentrates: an example of pharmacovigilance with fibrinogen and factor XIII-concentrate].
Spannagl M; Joch Ch; Heindl B
Hamostaseologie; 2006 Aug; 26(3 Suppl 1):S36-40. PubMed ID: 16953291
[TBL] [Abstract][Full Text] [Related]
15. Toward reducing perioperative transfusions.
Joyce JA
AANA J; 2008 Apr; 76(2):131-7. PubMed ID: 18478819
[TBL] [Abstract][Full Text] [Related]
16. [Viral inactivation of cellular blood products].
Andreu G
Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):215-6. PubMed ID: 8337130
[No Abstract] [Full Text] [Related]
17. Are inactivation procedures for blood products good or bad?
Caspari G
BMJ; 2002 Nov; 325(7372):1116. PubMed ID: 12424183
[No Abstract] [Full Text] [Related]
18. Viral inactivation of blood components: recent advances.
Horowitz B; Ben-Hur E
Transfus Clin Biol; 1996; 3(1):75-7. PubMed ID: 8640317
[No Abstract] [Full Text] [Related]
19. When do we transfuse cryoprecipitate?
Anderson MA; Glazebrook B; Cutts B; Stevenson L; Bielby L; Borosak M
Intern Med J; 2013 Aug; 43(8):896-902. PubMed ID: 23425520
[TBL] [Abstract][Full Text] [Related]
20. Cryoprecipitate: the current state of knowledge.
Callum JL; Karkouti K; Lin Y
Transfus Med Rev; 2009 Jul; 23(3):177-88. PubMed ID: 19539873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
